Floatz logo

Ambroxol

Parkinson Disease

University College, LondonSmall moleculePhase 3Active
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
65/ 100
Competitive Position
65/ 100

Competitive context

255 Active assets in the Parkinson Disease cohort.

Asset / SponsorPhaseRating
Safinamide
Zambon SpA
Phase 4A
Cvt-301
Acorda Therapeutics
Phase 3A
Pardoprunox
Abbott Products
Phase 3BBB
Tvp-1012
Guangzhou Henovcom Bioscience Co. Ltd.
Phase 4BBB
Istradefylline
Georgetown University
Phase 4BBB

View all 50 →

Same molecule, other indications

Ambroxol is also rated in:

GBA1-related Parkinson disease, susceptibilityDormant
BB
Indicative ·
64 / 100
View asset →
mucus inspissation of respiratory tractDormant
BB
Indicative ·
64 / 100
View asset →
respiratory system disorderDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →